RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
Elena Élez(Vall d'Hebron Hospital Universitari), Rodrigo A. Toledo(Instituto de Salud Carlos III), Gráinne Kerr(Novartis (Switzerland)), Rossana Intini(Istituto Oncologico Veneto), Josep Tabernero(Deaconess Hospital), David P. Kodack(Novartis (United States)), Raquel Pérez-López(Vall d'Hebron Institut de Recerca), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Alejandro Piris‐Giménez(Vall d'Hebron Hospital Universitari), Ana Belén Moreno-Cárdenas(Vall d'Hebron Hospital Universitari), Roberta Fasani(Vall d'Hebron Institute of Oncology), Aldo Montagna(Istituto Oncologico Veneto), Sara Lonardi(Istituto Oncologico Veneto), Ron Smits(Unknown), Giovanni Randon(Fondazione IRCCS Istituto Nazionale dei Tumori), Ana Vivancos(Vall d'Hebron Institute of Oncology), R. Comas(Vall d'Hebron Hospital Universitari), Javier Gonzalo‐Ruiz(Vall d'Hebron Hospital Universitari), Javier Ros(University of Campania "Luigi Vanvitelli"), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Chiara Cremolini(University of Pisa), Diana Graus(Novartis (Switzerland)), J. Fernández(Max Planck Institute for Physics), Rodrigo Dienstmann(Universitat de Vic - Universitat Central de Catalunya), Carlota Arenillas(Universitat Autònoma de Barcelona), Shanshan Li(Shanghai Jiao Tong University), Marco Maria Germani(University of Pisa), Ariadna García(Vall d'Hebron Hospital Universitari), Kinga Bernatowicz(Vall d'Hebron Hospital Universitari)
Cited by 111
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k